Cynosure (Nasdaq: CYNO) is expected to report Q3 earnings on Oct. 23. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cynosure's revenues will grow 22.4% and EPS will decrease -300.0%.

The average estimate for revenue is $34.6 million. On the bottom line, the average EPS estimate is $0.12.

Revenue details
 Last quarter, Cynosure reported revenue of $39.6 million. GAAP reported sales were 50% higher than the prior-year quarter's $26.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.20. GAAP EPS were $0.20 for Q2 compared to -$0.10 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 58.2%, 100 basis points better than the prior-year quarter. Operating margin was 12.4%, 1,690 basis points better than the prior-year quarter. Net margin was 6.8%, 1,170 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $148.8 million. The average EPS estimate is $0.60.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 369 members out of 383 rating the stock outperform, and 14 members rating it underperform. Among 87 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 80 give Cynosure a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is buy, with an average price target of $26.25.